Glenmark Pharmaceuticals Limited (Glenmark) has launched a novel fixed-dose combination (FDC) drug – Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India. Glenmark has launched this FDC under the brand name Indamet. Glenmark is the first company in India to market the innovative FDC of Indacaterol, a long-acting beta-agonist and Mometasone Furoate, an inhaled corticosteroid that is approved by the DCGI (Drug Controller General of India).
“We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India; offering a world-class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma”, said Alok Malik, Group Vice-President & Head (India Formulations), Glenmark Pharmaceuticals Limited.
Indamet will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively, to be taken once daily.
